GleamWall
中文EN

ASMB ASSEMBLY BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1426800 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY80.2%
TTM net income YoY71.2%
TTM EPS YoY116.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-31.8%
Net margin-16.6%
FCF margin-60.7%
EBITDA margin-31.7%

Returns

ROE-4.6%
ROA-3.9%
ROIC (approx.)-7.8%
Asset turnover0.24x

Leverage & solvency

Liabilities / assets8.1%
Debt / equity0.00x
Current ratio12.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.65x
Accruals ratio10.4%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.96M$13.37M$8.21M$42.47M$10.79M$9.63M$9.42M$7.36M
R&D expense$20.23M$14.92M$14.90M$17.25M$16.59M$16.12M$14.85M$14.28M
SG&A expense$6.14M$4.80M$4.68M$5.42M$5.08M$4.59M$4.51M$4.61M
Operating income-$23.41M-$6.34M-$11.37M$19.80M-$10.88M-$11.09M-$9.94M-$11.53M
Pretax income———$22.09M-$9.20M-$10.20M—-$10.41M
Income tax———$0$0$0—-$76,000
Net income-$20.26M-$3.86M-$9.08M$22.09M-$9.20M-$10.20M-$8.82M-$10.34M
EBITDA-$23.39M-$6.32M-$11.34M$19.83M-$10.85M-$11.06M-$9.91M-$11.50M
EPS (basic)-0.93-0.20-0.54—-0.72-1.33-1.17—
EPS (diluted)-0.93-0.20-0.54—-0.72-1.33-1.17—
Weighted avg. shares (diluted)21.78M18.85M16.90M—12.69M7.66M7.51M—
Balance sheet
Cash & equivalents$29.07M$32.29M$31.12M$58.45M$22.53M$24.01M$23.41M$38.34M
Short-term investments$285.19M$288.07M$195.48M$189.66M$210.02M$50.97M$67.61M$73.73M
Receivables$582,000$822,000$451,000$974,000$912,000——$0
Current assets$321.16M$327.98M$232.61M$254.55M$236.81M$77.47M$95.53M$115.50M
PP&E, net$291,000$315,000$214,000$221,000$229,000$219,000$251,000$284,000
Total assets$325.29M$330.83M$235.51M$257.59M$240.00M$80.78M$99.02M$119.17M
Current liabilities$24.92M$23.45M$35.00M$48.78M$53.38M$47.29M$46.63M$47.80M
Total liabilities$26.49M$25.18M$36.90M$50.84M$57.30M$62.68M$71.88M$85.81M
Shareholders' equity$298.79M$305.65M$198.61M$206.75M$182.69M$18.10M$27.13M$33.36M
Shares outstanding20.37M19.85M15.89M15.86M15.82M7.67M7.62M7.46M
Cash flow statement
Operating cash flow-$17.16M-$15.49M-$22.10M$14.24M-$15.13M-$16.76M-$23.44M-$407,000
Capital expenditure$121,000$0$19,000$24,000$42,000$0$0$0
Free cash flow-$17.29M-$15.49M-$22.12M$14.21M-$15.18M-$16.76M-$23.44M-$407,000
Investing cash flow$3.51M-$92.08M-$5.38M$21.22M-$158.27M$16.99M$6.59M-$6.70M
Financing cash flow$10.44M$108.73M$149,000$456,000$171.93M$357,000$1.92M$17.00M
Depreciation & amortization$24,000$20,000$26,000$32,000$32,000$32,000$33,000$32,000
Stock-based compensation$3.32M$2.42M$1.12M$1.46M$1.67M$834,000$712,000$751,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.